Posted on

CANNABINOID PROFILE – CANNABIGEROL (CBG)

Here are highlights from studies and scientific review of the phyto cannabinoid Cannabigerol (CBG), demonstrating potential in promoting anti-cancer, anti-tumor, anti-inflammatory, anti-bacterial and anti-depressant effects, among other reported benefits.

HIGHLIGHTS

CBG elicits hyperphagia, by reducing latency to feed and increasing meal frequency, without producing negative neuromotor side effects.

CBG is a novel, well-tolerated appetite stimulant in pre-satiated rats.

CBG has remarkable anticancer properties in basic research models, it has proved to be an effective cytotoxic in high dosage on human epithelioid carcinoma and is one of the more effective phytocannabinoids against breast cancer (Baek et al., 1998; Ligresti et al., 2006)

CBG was show to slow the proliferation of tumor cells in vitro and in vivo. CBG was evaluated for anti-tumor efficacy against mouse skin melanoma cells and showed a significant in vivo activity using an methylthiazoltetrazolium (MTT)-based cell viability assay.

It is a relatively potent TRPM8 antagonist for possible application in prostate cancer and detrusor overactivity and bladder pain (De Petrocellis & Di Marzo, 2010; Mukerji et al., 2006). CBG can also antagonize the stimulation of serotonin 5-HT1A and CB1 receptors with significant efficiency.

CBG is shown to have an analgesic effect and reduce pain.

CBG demonstrates antierythemic effects and its ability to block lipooxygenase were said to surpass those of THC (Evans, 1991). CBG may stimulate a range of receptors important for pain, inflammation, and heat sensitization.

CBG behaves as a potent α2-adrenoreceptor agonist, supporting analgesic effects previously noted, and moderate 5-HT1A antagonist suggesting antidepressant properties (Cascio et al., 2010; Formukong, Evans, & Evans, 1988) Cascio, M. G., Gauson, L. A., Stevenson, L. A., Ross, R. A., & Pertwee, R. G. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent α2‐adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British journal of pharmacology, 159(1), 129-141.

CBG has significant antidepressant effects in the rodent tail suspension model and is a mildly antihypertensive agent (Maor, Gallily, & Mechoulam, 2006; Musty & Deyo, 2006)

CBG acts as an antibacterial agent. CBG is a strong AEA uptake inhibitor and a powerful agent against MRSA (methicillin-resistant Staphylococcus aureus) (Appendino et al., 2008; De Petrocellis et al., 2011)

CBG demonstrated modest antifungal effects (ElSohly, Turner, Clark, & Eisohly, 1982)

CBG eases the symptoms of psoriasis. CBG inhibits keratinocyte proliferation suggesting utility in psoriasis (Wilkinson & Williamson, 2007)

CBG has an anti-inflammatory effect and shows potential in inflammatory bowel disease, colorectal cancers, and Huntington’s disease.  Recent evidence identifies CBG as a potential candidate for treatment of colon cancer (Ligresti et al., 2006)

CBG is indicated in Glaucoma, and shown to relieve intraocular pressure

CBG had the strongest potency to inhibit platelet aggregation

ADDITIONAL REFERENCES

https://pubmed.ncbi.nlm.nih.gov/27503475/

  • PMID: 27503475
  • PMCID: PMC5021742
  • DOI: 10.1007/s00213-016-4397-4

Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021502/

https://clinicaltrials.gov/ct2/show/NCT04859296

https://www.sciencedirect.com/topics/neuroscience/cannabigerol